The targets of new potential AD drugs are mainly processes related to Aβ and P-tau neurotoxicity, mitochondrial dysfunction, oxidative stress, metabolic disorders, and neuroinflammation [18,19,20]. This evidence concerns the gene MAPT and Alzheimer disease.